Pemphigus vulgaris is an autoimmune bullous dermatosis that affects between 0,1 and 0,5%000 of the population. The prognosis of the disease is determined by the severity of the side effects of corticosteroid therapy and their compensation. The present study covered 52 patients with pemphigus vulgaris treated in the Clinic of Dermatology and Venereology, Prof. P. Stoyanov Medical University of Varna, during a 10-year period (1990-2000). There were 20 males aged between 28 and 86 years and 32 females aged between 17 and 77 years. The adverse effects of the corticosteroids in the patients with pemphigus vulgaris and their influence on the course of the disease were described. The combination with a cytostatic drug (cyclophosphamide or imuran) proved to be effective in reducing the total course and maintenance dosage of the corticostteroids in these patients.
Carson, P. J . , A . Hameed, A. R . Ahmed. Influence of treatment on the clinical course of pemphigus vulgaris.- J. Am. Acad. Dermatol., 34, 1996, No 4, 645-652.
Fellner, M. J . , A . N . Sapadin. Current therapy of pemphigus vulgaris. - Ml Sinai J. Med., 68, 2001, No 4-5, 268-278
.
Fox, L . P., A. G. Pandya. Pulse intravenous cyclophosphamide therapy for dermatologic disorders.- Dermatol. Clin., 18, 2000, No 3, 459-473.
Jolles, S. A review of high-dose intravenous immunoglobulin (hdivIG) in the treatment of the autoimmune blistering disorders.- Clin. Exp. Dermatol., 26, 2001, No 2, 127-131.
Korman, N . J . New and emerging therapies in the treatment of blistering diseases.- Dermatol. Clin., 18, 2000, No 1, 127-137.
Korman, N . J . New immunomodulating drugs in autoimmune blistering diseases.- Dermatol. Clin., 19, 2001, No 4, 637-648.
Lever, W. F . , G . Schaumburg-Lever. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982.- Arch. Dermatol. Res., 120, 1977, No 1,44-47.
Mignogna, M. D. , L. Lo Muzio, R. E . Mignogna, R. Carbone, E . Ruoppo, E . Bucci . Oral pemphigus: long term behaviour and clinical response to treatment with deflazacort in sixteen cases.- J. Oral Pathol. Med., 29, 2000, No 4, 145-152.
Scully, C , S. J . Challacombe. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management.- Crit. Rev. Oral Biol. Med., 13, 2002, No 5, 397-408.
Seidenbaum, M., M. David, M. Sandbank. The course and prognosis of pemphigus. A review of 115 patients.- Int. J. Dermatol., 27, 1988, No 8, 580-584
Email this article (Login required) 
